



ASX & Media Release

Finance update

Melbourne, Australia; May 1, 2017: Patrys Limited (**ASX: PAB**) a therapeutic antibody development company is pleased to announce that it has received \$394,947 as the final tranche of an agreement regarding amounts due from a contracting party. This final tranche brings the settlement total to approximately \$730,000.

“We are very pleased to have completed the negotiation for these monies and are working diligently to maximize other non-dilutive capital inflows including insurance recoveries,” said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. “These funds will be used to fund company operations, including the development of the PAB-DX1 program through pre-clinical studies as we progress what we believe to be an increasingly exciting early stage asset.”

-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Patrys IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au

Patrys Media:

Kellie Stanborough
Buchan Consulting
P: +61 3 9866 4722
kstanborough@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.